Clinical Trial Update: Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout

View source ↗

Summary

An observational study evaluating the use of pegloticase (KRYSTEXXA) in patients with refractory chronic gout; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• KRYSTEXXA (pegloticase)

Snippet

Sponsor: Horizon Pharma Rheumatology LLC | Conditions: Refractory Chronic Gout | Status: COMPLETED | Results posted: 2019-01-11